Clinical Trial Detail

NCT ID NCT03523585
Title DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.

Her2-receptor positive breast cancer


Trastuzumab deruxtecan

Capecitabine + Lapatinib

Capecitabine + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST